identifying a test compound as a potential anti-cancer drug if it inhibits activity of said protein.

96. The method of claim 95 wherein the mRNA is induced in breast tumors.

97. The method of claim 95 wherein the mRNA is induced in BT-474 breast tumor cells.

98. The method of claim 95 wherein the mRNA is selected from those shown in Table 3.

99. A solid support comprising an array of nucleic acid probes, wherein at least 50 of said probes comprise a portion of at least 9 contiguous nucleotides of a gene identified in Table 3.

100. The solid support of claim 99 wherein at least 75 of said probes comprise a portion of at least 9 contiguous nucleotides of a gene identified inTable 3.

101. The solid support of claim 99 wherein at least 100 of said probes comprise a portion of at least 9 contiguous nucleotides of a gene identified inTable 3.

102. The solid support of claim 99 wherein at least 150 of said probes comprise a portion of at least 9 contiguous nucleotides of a gene identified inTable 3.

103. The solid support of claim 99 wherein at least 200 of said probes comprise a portion of at least 9 contiguous nucleotides of a gene identified inTable 3.

104. The solid support of claim 99 wherein at least 250 of said probes comprise a portion of at least 9 contiguous nucleotides of a gene identified inTable 3.

105. The solid support of claim 99 wherein at least 300 of said probes comprise a portion of at least 9 contiguous nucleotides of a gene identified inTable 3.

106. The solid support of claim 99 comprising probes selected from those shown in Table 2.

107. The method of claim 7 wherein said biological samples are prepared using random chemical mutagenesis.

108. The method of claim 7 wherein said biological samples are prepared using microinjection of antisense RNA or protein into cells.